ONC:NASDAQ
BeOne Medicines AG
၃၆၂.၃၈ US$
arrow_downward
-၀.၁၁%(-၀.၄၀) 1D
အောက် ၇, GMT-၄ ၀၉:၅၀:၄၃ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ONC...
Open
၃၆၀.၀၁ US$
High
၃၆၂.၃၈ US$
Low
၃၅၉.၄၁ US$
Mkt. cap
ဋေ ၄.၄၃ ထ
Avg. vol.
၃.၇၄ သိန်း
Volume
၁.၅၅ သောင်း
52-wk high
၃၈၅.၂၂ US$
52-wk low
၂၅၃.၉၅ US$
Beta
၀.၆၁
Shares outstanding
၁၀.၉၈ ကုဋေ
No. of employees
၁ သောင်း
Open
၃၆၀.၀၁ US$
High
၃၆၂.၃၈ US$
Low
၃၅၉.၄၁ US$
Mkt. cap
ဋေ ၄.၄၃ ထ
Avg. vol.
၃.၇၄ သိန်း
Volume
၁.၅၅ သောင်း
52-wk high
၃၈၅.၂၂ US$
52-wk low
၂၅၃.၉၅ US$
Beta
၀.၆၁
Shares outstanding
၁၀.၉၈ ကုဋေ
No. of employees
၁ သောင်း
News stories
From web sources and news partners
MarketBeat
·
ပြီးခဲ့သည့် ၁ နာရီ
BeOne Medicines (NASDAQ:ONC) Stock Rating Cut to Hold at Zacks Research
AD HOC NEWS
·
ပြီးခဲ့သည့် ၁၂ နာရီ
BeOne Medicines stock gained 1.00 percent on October 5 as targets rose
TipRanks
·
ပြီးခဲ့သည့် ၁ ရက်
BeOne Medicines Grants New RSUs to 277 Employees Under Incentive Plan
Profile
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
About BeOne Medicines AG
CEOJohn Vincent Oyler | John Vincent Oyler
Employees၁.၂ သောင်း
Founded၂၀၁၀ အောက် ၂၈
Headquarters-
Sector-
Websitebeonemedicines.com